Monopar Therapeutics (MNPR) Change in Accured Expenses (2017 - 2025)

Monopar Therapeutics has disclosed Change in Accured Expenses across 9 years of filings, most recently posting $738682.0 for Q4 2025.

• Change in Accured Expenses for Q4 2025 came in at $738682.0, down 34.92% year-over-year; the trailing twelve-month figure through Dec 2025 was $388218.0 (down 23.4% YoY), and the FY2025 annual result was $388218.0, down 23.4% from the prior year.
• Change in Accured Expenses came in at $738682.0 for Q4 2025 at Monopar Therapeutics, up from $355101.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.2 million in Q4 2022 to a low of -$770968.0 in Q1 2025.
• The 5-year median for Change in Accured Expenses is $13156.5 (2022), against an average of $72187.0.
• Across the five-year window, Change in Accured Expenses slumped 10489.49% in 2023 and jumped 1137.63% in 2025, its largest moves.
• Monopar Therapeutics' Change in Accured Expenses stood at $403967.0 in 2021, then jumped by 196.03% to $1.2 million in 2022, then tumbled by 117.81% to -$212999.0 in 2023, then surged by 632.91% to $1.1 million in 2024, then sank by 34.92% to $738682.0 in 2025.
• The last three Change in Accured Expenses figures came in at $738682.0 (Q4 2025), $355101.0 (Q3 2025), and $65403.0 (Q2 2025), per Business Quant data.